Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1963 1
1967 1
1971 1
1973 1
1990 2
1993 2
1994 4
1995 1
1996 1
1997 5
1999 2
2000 3
2001 2
2002 6
2003 3
2004 7
2005 3
2006 3
2007 5
2008 5
2009 1
2010 3
2011 3
2012 4
2013 2
2014 2
2015 6
2016 7
2017 6
2018 12
2019 7
2020 5
2021 5
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29035395

109 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher MA, Bence-Bruckler I, Laneuville P, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK. Flowers CR, et al. Biol Blood Marrow Transplant. 2016 Jul;22(7):1197-1205. doi: 10.1016/j.bbmt.2016.03.018. Epub 2016 Mar 31. Biol Blood Marrow Transplant. 2016. PMID: 27040394 Free PMC article. Clinical Trial.
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
Sakellari I, Gavriilaki E, Bouziana S, Constantinou V, Mallouri D, Vardi A, Marvaki A, Batsis I, Sotiropoulos D, Anagnostopoulos A. Sakellari I, et al. Bone Marrow Transplant. 2019 Jun;54(6):921-923. doi: 10.1038/s41409-018-0395-y. Epub 2018 Nov 8. Bone Marrow Transplant. 2019. PMID: 30410083 No abstract available.
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, Artz A, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson R, Saber W, McCarthy P, Pasquini MC. Chen YB, et al. Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. doi: 10.1016/j.bbmt.2015.02.005. Epub 2015 Feb 14. Biol Blood Marrow Transplant. 2015. PMID: 25687795 Free PMC article.
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I, Mallouri D, Batsis I, Apostolou C, Konstantinou V, Abela EM, Douka V, Marvaki A, Karypidis K, Iskas M, Baliakas P, Kaloyannidis P, Yannaki E, Sotiropoulos D, Kouvatseas G, Smias C, Anagnostopoulos A. Sakellari I, et al. Leuk Lymphoma. 2015;56(11):3071-81. doi: 10.3109/10428194.2015.1028054. Epub 2015 Apr 7. Leuk Lymphoma. 2015. PMID: 25760637
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT. Carella AM, et al. J Clin Oncol. 2000 Dec 1;18(23):3918-24. doi: 10.1200/JCO.2000.18.23.3918. J Clin Oncol. 2000. PMID: 11099321 Clinical Trial.
109 results